Thursday, 26 March 2020

Cough Syrup Market Size, Share, Development, Growth and Demand Forecast to 2024

Global Cough Syrup Market: Information by Product Type (Combination {Dextromethorphan + Guaifenesin, Guaifenesin + Pseudoephedrine and Brompheniramine + Pseudoephedrine} and Individual {Dextromethorphan, Guaifenesin, Ambroxol and Codeine}), by Category (Cough Suppressants and Expectorants), by Application (Adults and Children) and by Region ( Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2026
Market Scenario:
The Global Cough Syrup Market Statistics expects to register a CAGR of 3.45% to reach USD 5,139.63 million by 2026. Cough syrups are the medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.
The increasing incidence of respiratory disorders along with the rising air pollution are some of the key factors contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with an active pharmaceutical sector, are boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.
However, product recalls, and the stringent regulatory scenario are hampering the growth of the Cough Syrupmarket size.
Market Dynamics
Rising air pollution is acting as a driver for the growth of the market. Air pollution is a major environment-related health threat that stands as a risk factor for both acute and chronic respiratory diseases. According to a report by the Forum of International Respiratory Societies (FIRS), tobacco smoke, indoor air pollution from burning fuels, and air pollution from traffic and industrial sources are highlighted as the primary contributing factors for most respiratory conditions. World Health Organization (WHO) estimated that 4.3 million deaths per year could be attributed to indoor air pollution. Most diseases and deaths that can be attributed to prolonged exposure to poor indoor air quality occurs primarily in women and children, especially in low-income families. Exposure to indoor smoke used for heating and cooking leads to COPD, lung cancer, and, in children, it causes pneumonia and asthma. This large population affected with respiratory disorders due to air pollution is driving the market for cough syrup market as it is a crucial medicine used for the treatment of such diseases.
Segmentation
The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further classified as dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, and brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, the market has been segmented into cough suppressants and expectorants. And by application, the cough syrup market has been categorized as adults and children.
Regional Analysis
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region to combat these concerns effectively through the use of cough syrups.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.
Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory disorders due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.
The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable incomes of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Key Players
The prominent players in the global cough syrup market are Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France).
The players operating in the global cough syrup market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In February 2019, Merck invested USD 70 million to expand its research & development (R&D) facility in Billerica, Massachusetts for the development of innovative clinical pipeline products.
  • In July 2018, Johnson & Johnson acquired Zarbee's Naturals, a drug-free children's cough syrup. This enabled the company to broaden its product portfolio globally.
  • In December 2016, Pfizer, Inc., launched a series of products as a line extension under the Corex brand name. The first launch was on December 2016, and subsequent launches were conducted in 2017. These formulations were duly approved by central and state regulators.
Key Players
  • DJO Global, Inc. (US)
  • BTL Industries (US)
  • Enraf-NoniUS B.V (Europe)
  • Dynatronics Corporation (US)
  • EMS Physio (UK)
  • ITO Co. Ltd (Japan)
  • Mectronic Medicale (Europe)
  • Performance Health (Subsidiary of Madison Dearborn Partners) (US)
  • Whitehall Manufacturing (US)
  • Zimmer Medizinsysteme GmbH (Germany)
  • Colfax Corporation (US)
  • STORZ MEDICAL (US)
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Veterinary Imaging Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2025

Market Scenario
The Global Veterinary Imaging Market is expected to register a CAGR of 7.14% to reach USD 2167.78 million by 2025. Veterinary imaging is the noninvasive method that helps to diagnose disease by making medical images of the veterinary body. We have various advanced imaging technology used for veterinary patients. Veterinary imaging instruments are used to diagnosis of chronic disease and getting medical images of animals. Notably, the increasing prevalence of zoonotic diseases, significant rise in pet insurance purchases, and increased number of veterinary practitioners are promoting the growth of the veterinary imaging market globally.
The market growth is mainly driven by increasing incidence of zoonotic diseases, increasing expenditure on pet insurance, and technological advancements in veterinary imaging. However, high procedure cost and lack of skilled veterinarians may slow the growth of the market.
Market Dynamics
Increasing expenditure on the pet is driving the growth of the Veterinary Imaging market demand. Pet insurance covers various minor to major medical expenses such as accidents, chronic conditions, wellness, and routine care coverage, medication coverage, diagnostic testing and imaging, others. Though pet insurance does not provide 100% coverage, it reimburses around 80% of the total pet medical expenses. According to the North American Pet Health Insurance Association (NAPHIA), North America’s pet health insurance growth was exceeded by 17.2% from 2014 to 2015. It is also reported that the total number of insured pets reached 1.6 million at the end of 2015.
Pet owners spend a lot on routine vet expenses and surgical vet visits. As per the data suggested by The American Pet Products Association (APPA), around 65% of the US population owns a pet, and the US pet industry expenditure in 2015 was USD 60.3 million, which is exceeded to USD 62.8 million. Thus, with the growing spending on animal healthcare, the demand for veterinary diagnosis and the equipment required for the same will also increase, which boosts the growth and veterinary imaging market size.
Segmentation
The global veterinary imaging market is segmented into product type, animal type, therapeutic area, and end user. On the basis of product type, the market is segmented into instruments, veterinary imaging reagents, and veterinary software. On the basis of animal type, it is segmented into small companion animals and large animals. On the basis of the therapeutic area, the veterinary imaging market segmented into orthopedics and traumatology, cardiology, neurology, and oncology. On the basis of end user, the Veterinary Imaging market segmented into hospitals & clinics, and academic institutes.
Regional Analysis
The global veterinary imaging market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2018, and the regional market is projected to register a CAGR of 7.62% during the forecast period. The larger share is majorly attributed to the growth in adoption of pet animals, increasing veterinary healthcare expenditure, increasing demand for pet insurance, and increasing pet ownership. According to the report published by the American Pet Products Association, from 2017 to 2018, 68% of the US households or 85 million families have a pet.
Europe is the second-largest market for veterinary imaging owing to the presence of large market players, innovative advanced technology, increasing companion animal ownership, and the presence of veterinaries.
The Asia Pacific region accounted the third-largest market owing to the presence of large animal population, increasing disposal income, increasing nuclear families preferring to have pets and increased investments by the American and European market giants in Asian countries such as China and India. India held a share of 15.9% in the Asia-Pacific veterinary imaging market in 2018.
The market in the Middle East and Africa is constrained due to poor development of the animal industry and the low productivity of the maximum breeds in the region.
Key Players
The prominent players in the global veterinary imaging market are Esaote SpA (Italy), GE Healthcare (US), Medical Imaging/IMCO, Inc. (US), BCF (Scotland), Fujifilm Holding Corporation (Japan), Heska Corporation (US), Diagnostic Imaging System, Inc. (US), Canon Inc. (Tokyo), Carestream Health (US), and Merry X-Ray (US).
The players operating in the global veterinary imaging market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In March 2019, Esaote SpA launched the new ultrasound platform MyLabX8 for increasing efficiency of ultrasound machines and to maintain the workflow.
  • In October 2018, GE Healthcare announced a strategic collaboration with SonoSim to encourage education and training about ultrasound devices. This collaboration is likely to help the company to increase its customer base.
  • In June 2018, Fujifilm Holding Corporation acquired Irvine Scientific Sales Company, Inc. for USD 800 million. With this acquisition, Fujifilm is likely to enter into the cell culture media business.
Detailed Table of Contents:
1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition 
3.2 Scope Of The Study
3.3 List Of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increasing Incidence Of Zoonotic Diseases
5.2.2 Increasing Expenditure On Pet Insurance 
5.2.3 Technological Advancements In Veterinary Imaging
5.3 Restraints
5.3.1 High Procedure Cost
5.3.2 Lack Of Skilled Veterinarians
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Immunoassays in R&D Market to Quadruple by 2023; Foretells MRFR

Market Scenario
The Global Immunoassay In R&D Market Size is expected to register a CAGR of 8.18% and is anticipated to reach USD 475.3 million by 2023. Immunoassays are analytical methods in which the quantitation of the analyte depends on the reaction of an antigen and an antibody. Immunoassays incorporate a variety of different labels for the detection of antibodies and antigens. These labels are generally chemically linked or conjugated to the desired antibody or antigen.
The increasing incidence of chronic and infectious diseases, growing research and development investment (R&D) activities, and technological advancements are the major factors boosting the growth of the market. Despite the drivers, the high cost of immunoassay procedures and the high price of immunoassay systems constrain the growth of the market.
Market Players
Market Research Future (MRFR) recognizes the following companies as the key players in the global immunoassay in R&D market that includes Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (Germany), Becton, Dickinson and Company (US), Danaher Corporation (US), bioMérieux Inc. (France), Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Sysmex Corporation (Japan), and Abcam plc (United Kingdom).
Segment Analysis
The global immunoassay in R&D market has been segmented into type, application, and end user. By type, the market has been segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot Assay (ELISpot), Radioimmunoassay (RIA), Chemiluminescence (CLIA), Fluoroimmunoassay, and Others. On the basis of application, the market has been segmented into infectious diseases, cancer research, endocrinology, autoimmune diseases, and others. By end-user, the market has been segmented pharmaceutical and biotechnology companies, academic institutions and laboratories, and others
Regional Analysis
Geographically, the Americas is expected to dominate the global immunoassay in R&D market. The market growth is attributed to the increasing number of research projects in laboratories, growing adoption of advanced technology in research, and the growing prevalence of several diseases. The European market for immunoassay in R&D is expected to be the second-largest market due to the growing adoption in diagnostic measures is expected to boost the growth of the market in this region.
Moreover, the companies operating in the market are particularly focusing on mergers and acquisition which is expected to support the market growth. Asia-Pacific is estimated to be the fastest growing market due to the developing healthcare infrastructure and increasing disposable income. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the Asia-Pacific region, South Korea accounted for a market share of 10.1% in 2017. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.
Key Findings of the Study:
  • Global immunoassay in R&D market is projected to reach USD 3 million by 2023 with 8.18% CAGR during the review period of 2018 to 2023
  • Americas accounted for the largest immunoassay in R&D market share in the region due to the increasing number of research projects and the growing prevalence of chronic diseases
  • The pharmaceutical and biotechnology companies segment accounted for a market value of USD 174.3 million in 2017
Detailed Table Of Contents of Global Immunoassay in R&D Market
TABLE OF CONTENTS
1 Report Prologue
2 Market Introduction
2.1     Definition      
2.2     Scope Of The Study 
2.3     List Of Assumptions  
2.4     Market Structure     
3 Research Methodology
3.1     Research Process    
3.2     Primary Research    
3.3     Secondary Research
3.4     Market Size Estimation
3.5     Forecast Model
4 Market Dynamics
4.1     Overview      
4.2     Drivers         
4.2.1   Increasing Incidence Rate Of Chronic And Infectious Diseases
4.2.2   Increased R&D Investments By Public And Private Organizations
4.2.3   Technological Advancements In Immunoassay Testing   
4.3     Restraints     
4.3.1   High Cost Of Immunoassay Procedures    
4.3.2   High Price Of Immunoassay Systems       
4.4     Opportunity
4.4.1   Integration Of The Microfluidics Technology In Immunoassays
4.5     Challenge
4.5.1   Technical Difficulties During Testing
5 Market Factor Analysis
5.1     Value Chain Analysis
5.1.1   R&D And Product Development      
5.1.2   Manufacturing
5.1.3   Distribution & Sales 
5.1.4   Post-Sales Monitoring         
…TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Injectable Drug Delivery Devices Market 2019 Global Key Vendors Analysis, Revenue, Trends & Forecast to 2023

Market scenario:
The Global Injectable Drug Delivery Devices Market is expected to register 11.3% CAGR and is anticipated to reach USD 17,401.8 million by 2023. Injectable drug delivery devices, including conventional syringes, needle-free injectors, and auto and pen injectors, have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The global market for injectable drug delivery devices has witnessed continuously increasing R&D. As a result, the market is fragmented into various high-end and technologically advanced products. Following the illustrated course, it is projected that an increasing prevalence of chronic diseases, growing adoption of self-injectable devices, and rising FDA approvals drive the market growth. However, the presence of cross-contamination and increasing cost of high-end products are estimated to restrain the market growth during the forecast period.
Market Dynamics
The global injectable drug delivery devices prevalence of chronic diseases such as diabetes, heart diseases, multiple sclerosis, cancer, and arthritis have increased. According to the statistical report published by the American Diabetes Association, in 2017, ~30.3 million, i.e., 9.4% of the total population within the US had diabetes in 2015. Moreover, the fact sheet of 2018 published by the World Health Organization estimates cancer to be the second leading cause of death across the globe. The disease is estimated to cause ~9.6 million deaths in 2018. The other factors that are driving the global injectable drug delivery devices market are growing adoption of self-injectable devices, Rising FDA approvals for the drug delivery devices, and others.
Global Injectable Drug Delivery Devices Industry Size, by Site of Delivery, 2017 & 2023 (USD Million)
Segmentation
The global Injectable drug delivery devices market has been segmented into devices, therapeutic application, usage pattern, site of delivery, distribution channel, and facility of use.
Based on device, the global market is divided into conventional injection devices and self-injection devices.
Based on therapeutic application, the global market is segmented into autoimmune diseases, hormonal disorders, and cancer.
Based on usage pattern, the global market is divided into curative pattern and immunization.
Based on site of delivery, the global market is segmented into intramuscular, subcutaneous, and intradermal.
Based on distribution channel, the global market is divided into hospital & retail pharmacies and online platforms.
Based on facility of use, the global market is segmented into hospitals and clinics and home care settings.
Key Players
The prominent players in the global Injectable drug delivery devices market are Eisai Co., Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson Services Inc., Mylan N.V., Novartis AG, Novo Nordisk, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, and Inovio Pharmaceuticals Inc.
Regional Analysis
The global Injectable drug delivery devices market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to dominate the global injectable drug delivery devices market owing to the rising awareness about the condition and high healthcare expenditure. The region is expected to reach USD 17,401.8 million by 2023 with a CAGR of 11.3% from2018 to 2023. The Americas accounted largest regional market owing to the growing biotechnology industry, the ever-increasing prevalence of cancer and diabetes, and a well-developed healthcare sector.  
Europe accounted for the second-largest market share in 2017 due to extensive R&D in healthcare, increasing funding, and growing adoption of the devices within the region.
On the other hand, the Middle East & Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.
TABLE OF CONTENTS
  1. Report Prologue
  2. Market Introduction
2.1 Scope Of Study  
2.2 Research Objective
2.3 List Of Assumptions
  1. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
  1. Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Prevalence Of Chronic Diseases 
4.2.2 Growing Adoption Of Self-Injectable Devices
4.2.3 Rising FDA Approvals 
4.2.4 Drivers Impact Analysis
4.3 Restraints
4.3.1 Risks Of Cross-Contamination
4.3.2 Increasing Cost Of High-End Products
4.3.3 Restraints Impact Analysis
…Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Precision Medicine Market 2019 Global Trends, Share, Industry Size, Growth, Opportunities, and Industry Forecast to 2025

The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.
The global precision medicine market size was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2025. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2025.
Precision medicine evolved from the concept that same medicine cannot function equally for two different individuals with the same disease as they have different gene structure. At the same time, medication depends on how well patients can respond to its dosage. Hence, the need for precision medicine. Market Research Future (MRFR), in their report, has included various drivers and segments that can produce a reliable prediction for the future market. Prevalent diseases such as cancer, diabetes, and others are boosting the precision medicine market as treatment of such diseases gets a better result with personalized medicine structure. Furthermore, its impact can significantly lower the cost of treatment.
However, a personal data breach can be seen as a major precision medicine market growth prohibition. The diagnostic cost can incur a high cost, stringent government policies, the risk with hardware and software failure, and lack of medical framework can hold back the market during the forecast period.
Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine
Key Findings:
  • The global precision medicine market is expected to reach USD 88.64 billion by 2025.
  • By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2025.
  • By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2025.
Segmentation
The global precision medicine market has been segmented into ecosystem players, sub-markets, and therapeutics.
Based on ecosystem players, the global market has been segmented into pharmaceuticals and biotechnology companies, diagnostic companies, healthcare IT specialists/big data companies, and clinical laboratories. The diagnostic tool companies segment accounted for a market value of USD 16.27 million in 2017.
Based on sub-markets, the global market has been segmented into companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics (PGX), molecular diagnostics, and others.
Based on therapeutics, the global market has been segmented cancer/oncology, cardiovascular disease (CVD), central nervous system, infectious diseases, and others.
Regional Analysis
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.
List of Tables
Table 1 Leading Companies In The Precision Medicine Market 37 
Table 2 Downsizing Cost Of Genome Sequencing 74 
Table 3 Factors Impacting The Buyer’s Bargaining Power 80 
Table 4 Factors Impacting The Supplier’s Bargaining Power 81 
Table 5 Factors Impacting The Threat From Substitute 82 
Table 6 Factors Impacting The Threat From New Entrant 83 
Table 7 Factors Impacting The Degree Of Competition 84 
Table 8 Regulatory Bodies In Precision Medicine Market 87 
Table 9 Consortiums In Precision Medicine Market 93 
Table 10 Alliances/Associationsin Precision Medicine Market 94 
Table 11 Global Precision Medicine Market Value, By Ecosystem Players, 2014-2025 ($Billion) 97 
Table 12 Pharma & Biotech: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2025 ($Billion) 100 
List of Figures
Figure 1 Precision Medicine Market Study 27 
Figure 2 Research Methodology 29 
Figure 3 Different Phases Of Research Methodology For The Global Market 30 
Figure 4 Precision Medicine Market: Research Methodology 32 
Figure 5 Global Precision Medicine Market Share, By Ecosystem, 2014-2025 ($Billion) 38 
Figure 6 Global Precision Medicine Market Size, By Sub-Market Type, 2014 – 2025 (Billion) 39 
Figure 7 Global Precision Medicine Market Size, By Therpeutic Application, 2014 – 2025 (Billion) 40 
Figure 8 Global Precision Medicine Market Size, By Geography, 2014 – 2025 ($Billion) 41 
Figure 9 Timeline Of Precision Medicine 43 
Figure 10 Precision Medicine: Benefits 45 
Figure 11 Examples: Applied Areas Of Precision Medicine 46 
Figure 12 Elements Of Precision Medicine Technology 47 
Figure 13 Different Type Of Data Used By Big Data Companies 48 
Figure 14 Precision Medicine: Areas Of Interest 49 
Figure 15 Precision Medicine: Partnerships, Agreements, And Collaborations (2015) 53 
Figure 16 Precision Medicine: Mergers & Acquisitions( 2015) 55 
Figure 17 Precision Medicine: Key Product Launch & Developments (2015) 57 
...TOC Continued!   
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Global Pericarditis Market Analysis 2019 Forecasts to 2023

Market Synopsis of Global Pericarditis Market:
Global Pericarditis Market analysis by Type (Acute Pericarditis, Recurrent Pericarditis and Chronic Pericarditis), Diagnosis & Treatment [Diagnosis (Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (CT) and X-Ray) and Treatment (Medication (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Colchicine) and Surgical Treatment), End User (Hospitals & Clinics and Medical Institutes & Research Laboratories) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2023
Market Scenario:
Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.
The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the market.
The Global Pericarditis Market is expected to register 7.96% CAGR and is anticipated to reach USD 2,741.39 Million by 2023.
Market Dynamics
The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.
Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.
Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.
The market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.
Segmentation
The global pericarditis market has been segmented into type, application, and end user. 
Based on type, the global market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.
Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.
Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.
Key Players
The prominent players in the global pericarditis market are Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the other major players in the global market.
Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.
Regional Analysis
The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the global pericarditis market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.
The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.
Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.
Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.
Key Updates
  • In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
  • In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.
  • In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Pathological Microscopes Market Global Industry Review 2019 To 2023

Market Scenario
The growth of the healthcare sector in conjunction with the rising prevalence of diseases is expected to create demand for advanced equipment over the next couple of years. A study conducted by Market Research Future (MRFR) on the pathological microscopes market projects that a CAGR of 4.50% over the assessment period 2018 to 2023. The report further underlines that the market is expected to scale a valuation of USD 523.20 Mn towards the close of 2023.
The increasing burden of diseases such as cancer, diabetes, tuberculosis, etc. is anticipated to intensify the demand for pathological equipment that facilitates early detection and diagnosis. It is projected to pave the way for innovation and development of devices that offer accuracy. This, in turn, is anticipated to have a favorable impact on the growth pattern of the pathological microscopes market in the years to come.
The automation drive witnessed in the laboratories is also projected to accelerate revenue creation for market participants. Again, the increasing count of laboratories and pathology labs are expected to propel the expansion of the pathological microscopes market size over the next few years.
Competitive Analysis
Microscope manufacturers in the pathological microscopes market include Nikon Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Olympus Corporation (Japan), ZEISS International (Germany), Labomed, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Euromex Microscopen BV (The Netherlands), Bruker Corporation (U.S.), Sakura Finetek USA, Inc. (U.S.), and Celestron LLC (U.S.).
The players are focusing on integrating new technologies to expedite the diagnosis rate associated with microscopes and lower the mortality rate. Collaborations, new product launches, and partnerships are strategies being adopted to gain a larger market share.
Segmentation
The pathological microscopes market is segmented by type, application, and end-user.
By type, electron microscope held close to 41.4% share in 2017, followed by optical microscope (18.8%), compound microscope (13.5%), digital microscope (5.4%), fluorescence microscope (4.4%), and others (16.5%). Electron microscopes can generate nearly USD 217.81 million by 2023 owing to their application in life sciences. Prevalence of diseases such as anemia and leukemia which require the need of electron microscopes lend credence to the segment valuation. But digital microscopes can exhibit the highest CAGR of 5.01% during the forecast period to accumulate USD 28.90 million for the pathological microscopes market by 2023.
By end-user, pathology & diagnostic laboratories accounted for 45.2% market share in 2017, followed by hospitals & clinics (38.6%), forensic laboratories (11.5%), and others (4.7%). Hospitals & clinics will be the biggest end-user of the pathological microscopes market by 2023. It can generate USD 206.25 million by the end of the forecast period owing to the setup of various branches of hospital chains to handle high patient volume. On the other hand, pathology & diagnostic laboratories can generate USD 239.73 million by 2023 thanks to possessing various skilled personnel and use of hematology, clinical microbiology, and molecular pathology for rapid diagnosis of diseases.
By application, bodily fluids accounted for 79.4% share of the pathological microscopes market in 2017, followed by tissue scanning (12.7%), and others (7.9%). Bodily fluids can generate USD 418.84 million for the pathological microscopes market by 2023. This can be attributed to use of fluid samples to identify the presence of diseases such as tuberculosis in the human body. High prevalence of blood disorders is driving the segment growth. On the other hand, tissue scanning is touted to accumulate USD 67.94 million by 2023. High prevalence of cancer and use of digital microscopes to detect abnormal tissue growth can fuel the segment growth.
Regional Analysis
The global pathological microscopes market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas is expected to gain control over the maximum market share during the review period. The regional market is projected to touch a valuation of USD 190.98 Mn by the end of 2023. The advancements of laboratories being observed in the region are expected to drive the growth of the pathological microscopes market in the nearby future.
Asia Pacific is projected to exhibit healthy growth owing to the rapid developments in the healthcare sector. The pathological microscopes market in the region is anticipated to attract massive investments over the next couple of years, thus, augmenting the market.
Industry News:
In March 2019, Nikon Instruments Inc., a leader in advanced optical instruments, has announced a partnership with OptraSCAN, On-Demand Digital Pathology Solution Provider, for the launch of OS-15-N, a digital slide scanning system that features Nikon optics.
In January 2019, Roche, a Swiss multinational healthcare company, has announced the introduction of its uPath enterprise software for digital pathology.
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)